Skip to main content

Helicos Appoints Gene Myers to SAB; Metabolon Fleshes Out Brass; Mike Pellini Joins Safeguard Scientifics; and Others

NEW YORK (GenomeWeb News) — Helicos BioSciences has added Gene Myers to its scientific advisory board. Myers is a professor at the Janelia Farm Research Campus of the Howard Hughes Medical Institute.
 
Myers was vice president of informatics research at Celera Genomics.

Metabolon has appointed three new members to its executive team, the company said this week:
 
Tim Germann was named vice president of sales. He previously headed the sales and marketing branch of US Genomics and was involved in product launches at Affymetrix.
 
Bruce Mcreedy was named new vice president of strategic development. He was an associate vice president of infectious diseases with LabCorp and was associate vice president at Triangle Pharmaceuticals and CEO at Fulcrum
 
Dan Stevens has been named director of marketing. Stevens was formerly at Silicon Graphics and launched products at Procter and Gamble.

 
Xceed Molecular said this week it has appointed as president David Deems. He replaces Michael Cohen, who will become non-executive chairman of the board. 
 
Deems was previously vice president of development and operations at Predicant Biosciences, where he had also been vice president of development and operations. He was also vice president of product development at Exact Sciences, CEO of Union Biometrica, and was an executive at BD Biosciences.  

 
Safeguard Scientifics has added former Genomics Collaborative CEO Michael Pellini to its life sciences group as an executive in residence, the company said this week. In the position, Pellini will develop marketing opportunities, evaluate deals, and counsel the company on strategic development issues.
 
Most recently Pellini has served as COO of Lakewood Pathology Associates and was an entrepreneur in residence at BioAdvance.

 
Cepheid has renewed CEO John Bishop’s contract for four years to include a base salary of $450,000 and an annual bonus up to $225,000, the company said in a Securities and Exchange Commission filing this week.

The Scan

US Supports Patent Waivers

NPR reports that the Biden Administration has announced its support for waiving intellectual property protections for SARS-CoV-2 vaccines.

Vaccines Versus Variants

Two studies find the Pfizer-BioNTech SARS-CoV-2 vaccine to be effective against viral variants, and Moderna reports on booster shots to combat variants.

CRISPR for What Ails You

The Wall Street Journal writes that CRISPR-based therapies could someday be used to treat common conditions like heart attacks.

Nature Papers Review Integration of Single-Cell Assay Data, Present Approach to Detect Rare Variants

In Nature this week: review of ways to integrate data from single-cell assays, and more.